"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 |
| 1996 | 4 | 9 | 13 |
| 1997 | 2 | 5 | 7 |
| 1998 | 3 | 2 | 5 |
| 1999 | 6 | 2 | 8 |
| 2000 | 1 | 4 | 5 |
| 2001 | 3 | 6 | 9 |
| 2002 | 2 | 2 | 4 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 5 | 5 |
| 2005 | 1 | 5 | 6 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 6 | 7 |
| 2008 | 1 | 3 | 4 |
| 2009 | 4 | 3 | 7 |
| 2010 | 0 | 4 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 4 | 6 |
| 2015 | 0 | 5 | 5 |
| 2016 | 1 | 7 | 8 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 3 | 5 |
| 2019 | 0 | 6 | 6 |
| 2020 | 1 | 5 | 6 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 7 | 7 |
| 2024 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma. JCO Oncol Pract. 2025 Apr; 21(4):526-534.
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 01 15; 209(2):137-152.
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2024 Feb 01; 42(4):467-480.
-
Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy. Blood Adv. 2023 08 22; 7(16):4475-4478.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205.